Navigation Links
Breathe Technologies, Inc. Closes on $15 Million in Venture Funding Led by Kleiner Perkins Caufield & Byers
Date:3/26/2008

FREMONT, Calif., March 26 /PRNewswire/ -- Breathe Technologies, Inc., which is developing innovative, patient-friendly medical devices to treat respiratory problems associated with Chronic Obstructive Pulmonary Disease (COPD), cystic fibrosis, and influenza announced today that it has closed on $15 million in its second round of venture funding. The investment was led by Kleiner Perkins Caufield & Byers (KPCB) with participation from existing venture investors, including Synergy Partners International, Delphi Ventures and Life Science Angels.

"Breathe Technologies is developing unique, transformational technologies for patients with emphysema, chronic bronchitis and other respiratory ailments," said KPCB partner Beth Seidenberg, M.D., who joined the company's board of directors and was also formerly the Chief Medical Officer of Amgen. "More broadly, innovation in ventilator technology is crucial to help prepare our nation for potential pandemics such as influenza or other infectious agents. We believe Breathe Technologies has the potential to address these significant unmet needs."

Breathe Technologies is developing a unique family of compact, ultra-lightweight, ambulatory respiratory ventilator systems for the hospital, homecare and pandemic markets. Annual worldwide sales of conventional respiratory systems that the company's products could enhance or replace are estimated at more than $2 billion.

"Our goal is to improve the quality of life for people suffering from breathing disorders while reducing the high mortality rates associated with respiratory diseases," said Gregory J. Kapust, President and CEO of the company. "KPCB has a remarkable track record of partnering with companies that change industries and reshape markets. Our vision is to become the first provider of ultra-lightweight, truly patient-friendly ventilator systems that can transform respiratory care in the hospital and home."

Breathe Technologies, Inc., is locat
'/>"/>

SOURCE Breathe Technologies, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related medicine news :

1. Leading Health Groups Strongly Support the Minnesota Department of Healths Efforts to Enforce Freedom to Breathe Act
2. Breathe Easy. Play Hard.
3. BREATHE Lung Cancer Conference, Nov. 30, Offers Medical and Patient Education, Advocacy and Survivors Perspective
4. BODY WORLDS 2 & Breathe California Pair Up for Some Ash Kicking
5. BREATHE Lung Cancer Conference, Nov. 30, Attracts World Renowned Physicians and Speakers
6. Hundreds to Gather for Rally in Celebration of Right to Breathe Clean Air
7. Accordions Breathe Easier Since Smoking Ban
8. ReBuilder Medical Technologies, Inc. Announces Revolutionary Electronic Zapper Said to Destroy Molluscum Contagiosum Pathogen
9. Vital Health Technologies, Inc. / Caribbean American Health Resorts Inc. Acquires Momentum Medical Group, Inc.
10. Sandata Technologies, Inc. Adds TeleTimecard to its Service Offering
11. China Display Technologies, Inc. to Present at Roth Conference
Post Your Comments:
*Name:
*Comment:
*Email:
Other Medicine News:Health News:Americans United for Life Condemns Ruling Increasing Minors' Access to Dangerous Plan B 2Health News:AANS President to Testify on Patient Access to Care 2Health News:Transcept Pharmaceuticals Reports Fourth Quarter and Year End 2008 Financial Results 2Health News:Transcept Pharmaceuticals Reports Fourth Quarter and Year End 2008 Financial Results 3Health News:Transcept Pharmaceuticals Reports Fourth Quarter and Year End 2008 Financial Results 4Health News:Transcept Pharmaceuticals Reports Fourth Quarter and Year End 2008 Financial Results 5Health News:Transcept Pharmaceuticals Reports Fourth Quarter and Year End 2008 Financial Results 6Health News:Transcept Pharmaceuticals Reports Fourth Quarter and Year End 2008 Financial Results 7Health News:Transcept Pharmaceuticals Reports Fourth Quarter and Year End 2008 Financial Results 8Health News:Transcept Pharmaceuticals Reports Fourth Quarter and Year End 2008 Financial Results 9Health News:Transcept Pharmaceuticals Reports Fourth Quarter and Year End 2008 Financial Results 10Health News:Transcept Pharmaceuticals Reports Fourth Quarter and Year End 2008 Financial Results 11Health News:Transcept Pharmaceuticals Reports Fourth Quarter and Year End 2008 Financial Results 12Health News:Young Survival Coalition and Living Beyond Breast Cancer Announce Support for Rep. Wasserman Schultz's 'The Early Act' 2Health News:Lowest Blood Pressure, Cholesterol Levels the Best 2Health News:Lowest Blood Pressure, Cholesterol Levels the Best 3
Breaking Medicine Technology:Lentigen Awarded Phase I SBIR Grant for Hepatitis C Vaccine 2Medco, State of Illinois and Community Retail Pharmacies Launch 'Wired' Collaborative Solution to Close Critical Medication-Related Gaps in Healthcare, Improving Outcomes and Lowering Costs 2Medco, State of Illinois and Community Retail Pharmacies Launch 'Wired' Collaborative Solution to Close Critical Medication-Related Gaps in Healthcare, Improving Outcomes and Lowering Costs 3Medco, State of Illinois and Community Retail Pharmacies Launch 'Wired' Collaborative Solution to Close Critical Medication-Related Gaps in Healthcare, Improving Outcomes and Lowering Costs 4Medco, State of Illinois and Community Retail Pharmacies Launch 'Wired' Collaborative Solution to Close Critical Medication-Related Gaps in Healthcare, Improving Outcomes and Lowering Costs 5Cantel Medical Reports 85% Increase in Net Income - EPS of $0.37 vs. $0.20 - for Quarter Ended October 31, 2009 on 10% Sales Increase 2Cantel Medical Reports 85% Increase in Net Income - EPS of $0.37 vs. $0.20 - for Quarter Ended October 31, 2009 on 10% Sales Increase 3Cantel Medical Reports 85% Increase in Net Income - EPS of $0.37 vs. $0.20 - for Quarter Ended October 31, 2009 on 10% Sales Increase 4Cantel Medical Reports 85% Increase in Net Income - EPS of $0.37 vs. $0.20 - for Quarter Ended October 31, 2009 on 10% Sales Increase 5Cantel Medical Reports 85% Increase in Net Income - EPS of $0.37 vs. $0.20 - for Quarter Ended October 31, 2009 on 10% Sales Increase 6Valeant Grants Schering Plough Exclusive Option in Japan for Taribavirin in Exchange for Release of Last Right of Refusal 47437 1Valeant Grants Schering Plough Exclusive Option in Japan for Taribavirin in Exchange for Release of Last Right of Refusal 47437 2Valeant Grants Schering Plough Exclusive Option in Japan for Taribavirin in Exchange for Release of Last Right of Refusal 47437 3Rigels R788 Evaluated in Phase 2 Trial in Multiple Cancers 47432 1Rigels R788 Evaluated in Phase 2 Trial in Multiple Cancers 47432 2Rigels R788 Evaluated in Phase 2 Trial in Multiple Cancers 47432 3SAFC Pharmas St Louis HPAPI Conjugates Facility Receives SafeBridge Certification 47429 1SAFC Pharmas St Louis HPAPI Conjugates Facility Receives SafeBridge Certification 47429 2SAFC Pharmas St Louis HPAPI Conjugates Facility Receives SafeBridge Certification 47429 3